SCHEMBL14728320

SCHEMBL14728320

Cc1c(C(C)C)c(N2CCNCC2)n2c(nc3ccccc32)c1C#N

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.56
TP53 P04637 1/20 0.56
NPSR1 Q6W5P4 3/20 0.53
ALDH1A1 P00352 6/20 0.53
MEN1 O00255 3/20 0.53
KMT2A Q03164 3/20 0.53
LMNA P02545 3/20 0.53
KDM4E B2RXH2 5/20 0.51
CYP2C9 P11712 2/20 0.50
CYP2C19 P33261 1/20 0.50
CASP1 P29466 4/20 0.49
HSD17B10 Q99714 4/20 0.49
CASP7 P55210 3/20 0.49
TSHR P16473 3/20 0.49
HPGD P15428 1/20 0.49
GLA P06280 3/20 0.49
GAA P10253 3/20 0.49
RXFP1 Q9HBX9 2/20 0.49
CYP3A4 P08684 1/20 0.48
HIF1A Q16665 2/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14728721 0.86 NPSR1 (0.56) MAPTNPSR1ALDH1A1MEN1KMT2A
SCHEMBL6317936 0.83 ALDH1A1 (0.55) MAPTNPSR1ALDH1A1MEN1KMT2A
SCHEMBL4780216 0.81 NPSR1 (0.60) MAPTNPSR1ALDH1A1MEN1KMT2A
SCHEMBL6317691 0.81 MAPT (0.51) MAPTTP53NPSR1ALDH1A1MEN1
SCHEMBL14728326 0.80 CYP2C9 (0.66) MAPTNPSR1ALDH1A1MEN1KMT2A
SCHEMBL14728602 0.79 ALDH1A1 (0.55) NPSR1ALDH1A1MEN1KMT2ALMNA
SCHEMBL14728310 0.78 NPSR1 (0.61) MAPTNPSR1ALDH1A1MEN1KMT2A
SCHEMBL14728335 0.78 NPSR1 (0.57) MAPTNPSR1ALDH1A1MEN1KMT2A
SCHEMBL6310647 0.78 MAPT (0.67) MAPTTP53NPSR1ALDH1A1MEN1
SCHEMBL14728450 0.77 ALDH1A1 (0.53) NPSR1ALDH1A1MEN1KMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8822688-B2 Imidazo[1,2-a]pyridine derivative ASTELLAS PHARMA INC. (JP) 2014-09-02 US disclosed
US-8822688-B2 Imidazo[1,2-a]pyridine derivative ASTELLAS PHARMA INC. (JP) 2014-09-02 US disclosed
US-20130053363-A1 IMIDAZO[1,2-a]PYRIDINE DERIVATIVE ASTELLAS PHARMA INC. (JP) 2013-02-28 US disclosed
US-20130053363-A1 IMIDAZO[1,2-a]PYRIDINE DERIVATIVE ASTELLAS PHARMA INC. (JP) 2013-02-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130053363-A1 IMIDAZO[1,2-a]PYRIDINE DERIVATIVE PDE4B, PDE4A, PDE4C MAPT 411/4885TP53 2549/4885NPSR1 2690/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.